We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$3.33M
Cap. Flow
-$9.09M
Cap. Flow %
-4.16%
Top 10 Hldgs %
53.49%
Holding
80
New
23
Increased
12
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$4.26M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.35M
4
SAGE
Sage Therapeutics
SAGE
+$3.05M
5
SNY icon
Sanofi
SNY
+$2.95M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.92M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.66M
3
ENSG icon
The Ensign Group
ENSG
+$5.27M
4
ARRY
Array Biopharma Inc
ARRY
+$4.92M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.72M

Sector Composition

Rank Sector Weight
1 Healthcare 72.69%
2 Real Estate 11.35%
3 Industrials 8.34%
4 Miscellaneous 6.63%
5 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QCP
1
DELISTED
Quality Care Properties, Inc.
QCP
$23.1M 10.57%
1,074,080
+43,419
+4% +$916K
RCM
2
DELISTED
R1 RCM Inc. Common Stock
RCM
$15.7M 7.18%
1,808,076
-101,811
-5% -$824K
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$15.3M 7.01%
226,902
+16,124
+8% +$902K
RDUS
4
DELISTED
Radius Health, Inc.
RDUS
$13.8M 6.32%
468,581
+134,843
+40% +$4.26M
GSK icon
5
GSK
GSK
$102B
$10.3M 4.72%
202,067
+20,800
+11% +$1.05M
SNY icon
6
Sanofi
SNY
$107B
$8.52M 3.9%
212,972
+75,000
+54% +$2.95M
SPY icon
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$8.14M 3.72%
30,000
-30,000
-50% -$8.1M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.5B
$7.94M 3.63%
84,257
+38,257
+83% +$3.35M
TLGT
9
DELISTED
Teligent, Inc
TLGT
$7.31M 3.34%
211,210
+56,172
+36% +$1.77M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$6.79M 3.11%
43,401
+19,401
+81% +$3.05M
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$6.67M 3.05%
150,845
-53,701
-26% -$2.21M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.7B
$6.25M 2.86%
63,493
-15,400
-20% -$1.53M
ENSG icon
13
The Ensign Group
ENSG
$10.1B
$5.96M 2.72%
177,540
-170,844
-49% -$5.27M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$137B
$5.92M 2.71%
34,822
-10,000
-22% -$1.55M
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.85M 2.68%
134,151
-86,637
-39% -$3.72M
ZGNX
16
PUT
DELISTED
Zogenix, Inc.
ZGNX
$5.45M 2.49%
+123,300
New +$5.08M
SRPT icon
17
Sarepta Therapeutics
SRPT
$2.2B
$5.29M 2.42%
+40,000
New +$3.77M
NVRO
18
DELISTED
NEVRO CORP.
NVRO
$3.78M 1.73%
47,279
-13,571
-22% -$1.13M
ABT icon
19
Abbott
ABT
$195B
$2.8M 1.28%
45,900
-2,000
-4% -$121K
ATHN
20
DELISTED
Athenahealth, Inc.
ATHN
$2.55M 1.16%
+16,000
New +$2.37M
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$2.34M 1.07%
52,523
+1,000
+2% +$48.6K
ANAB icon
22
AnaptysBio
ANAB
$1.67B
$2.32M 1.06%
+32,634
New +$2.74M
ABMD
23
DELISTED
Abiomed Inc
ABMD
$2.29M 1.05%
5,594
-1,500
-21% -$543K
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$2.16M 0.99%
+98,395
New +$2.26M
ARQL
25
DELISTED
Arqule Inc
ARQL
$2.07M 0.95%
+374,320
New +$1.43M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Eversept Partners held 80 positions worth $219M, up 1.5% from $215M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners withdrew a net $9.09M in Q2 2018, closing 8 positions and reducing 26 holdings. Its most notable exit was Ablynx NV, an estimated $9.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Eversept Partners opened a new position in Sarepta Therapeutics worth $5.29M.

  • Eversept Partners's largest Q2 2018 buy was Sarepta Therapeutics: 40,000 shares worth $5.29M.
  • Eversept Partners added most to Radius Health, Inc. in Q2 2018, an estimated $4.26M increase.
  • Eversept Partners's biggest Q2 2018 reduction was The Ensign Group, cutting an estimated $5.27M.
  • Eversept Partners fully exited Ablynx NV in Q2 2018, selling an estimated $9.92M.
  • Eversept Partners's ten largest holdings make up 53% of its $219M portfolio in Q2 2018.
  • Eversept Partners opened 23 new positions and closed 8 in Q2 2018.
  • Eversept Partners's portfolio value rose 1.5% quarter-over-quarter to $219M.

Based on Eversept Partners's 13F filing for Q2 2018, filed 14 Aug 2018.